Gyre Therapeutics (GYRE) Other Accumulated Expenses (2011 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Other Accumulated Expenses of $226000.0 for Q1 2026, down 0.88% year-over-year from $228000.0 in Q1 2025, and little changed quarter-over-quarter from $227000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Other Accumulated Expenses (2011 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Other Accumulated Expenses for 16 consecutive years, with $226000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses fell 0.88% year-over-year to $226000.0; the TTM figure through Mar 2026 stood at $226000.0 (down 0.88% YoY), while the FY2025 annual figure was $227000.0, changed 0.0% from the prior year.
- Other Accumulated Expenses steadied at $226000.0 in Q1 2026 per GYRE's latest filing, from $227000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $4.4 million in Q1 2022 and bottomed at $118000.0 in Q4 2022.
- Historically, Other Accumulated Expenses has averaged $957176.5 across 5 years, with a median of $743000.0 in 2023.
- Annual changes were most pronounced in 2022 — Other Accumulated Expenses sank 97.77% — and 2023, when it jumped 1060.17%.
- Gyre Therapeutics' Other Accumulated Expenses stood at $118000.0 in 2022, then surged by 1060.17% to $1.4 million in 2023, then tumbled by 83.42% to $227000.0 in 2024, then changed by 0.0% to $227000.0 in 2025, then dropped by 0.44% to $226000.0 in 2026.
- Business Quant data shows GYRE's Other Accumulated Expenses at $226000.0 in Q1 2026, $227000.0 in Q4 2025, and $228000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.09 Mn |
| Mar 31, 2026 | 226,000.00 |
| Dec 31, 2025 | 227,000.00 |
| Sep 30, 2025 | 228,000.00 |
| Jun 30, 2025 | 219,000.00 |
| Mar 31, 2025 | 228,000.00 |
| Dec 31, 2024 | 227,000.00 |
| Sep 30, 2024 | 1.29 Mn |
| Jun 30, 2024 | 1.48 Mn |
| Mar 31, 2024 | 1.36 Mn |
| Dec 31, 2023 | 1.37 Mn |
| Sep 30, 2023 | 917,000.00 |
| Jun 30, 2023 | 2.07 Mn |
| Mar 31, 2023 | 743,000.00 |
| Dec 31, 2022 | 118,000.00 |
| Sep 30, 2022 | 182,000.00 |
| Jun 30, 2022 | 948,000.00 |
| Mar 31, 2022 | 4.44 Mn |
| Dec 31, 2021 | 4.07 Mn |
| Sep 30, 2021 | 8.14 Mn |